• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

采用 D-最优混合设计研制微乳提高雷洛昔芬的口服生物利用度:优化及体内药代动力学研究。

Oral bioavailability enhancement of raloxifene by developing microemulsion using D-optimal mixture design: optimization and in-vivo pharmacokinetic study.

机构信息

a Department of Pharmacy , Sumandeep Vidyapeeth , Vadodara , India.

出版信息

Drug Dev Ind Pharm. 2018 Apr;44(4):687-696. doi: 10.1080/03639045.2017.1408643. Epub 2017 Dec 4.

DOI:10.1080/03639045.2017.1408643
PMID:29168671
Abstract

The objective of this work was to utilize a potential of microemulsion for the improvement in oral bioavailability of raloxifene hydrochloride, a BCS class-II drug with 2% bioavailability. Drug-loaded microemulsion was prepared by water titration method using Capmul MCM C8, Tween 20, and Polyethylene glycol 400 as oil, surfactant, and co-surfactant respectively. The pseudo-ternary phase diagram was constructed between oil and surfactants mixture to obtain appropriate components and their concentration ranges that result in large existence area of microemulsion. D-optimal mixture design was utilized as a statistical tool for optimization of microemulsion considering oil, S, and water as independent variables with percentage transmittance and globule size as dependent variables. The optimized formulation showed 100 ± 0.1% transmittance and 17.85 ± 2.78 nm globule size which was identically equal with the predicted values of dependent variables given by the design expert software. The optimized microemulsion showed pronounced enhancement in release rate compared to plain drug suspension following diffusion controlled release mechanism by the Higuchi model. The formulation showed zeta potential of value -5.88 ± 1.14 mV that imparts good stability to drug loaded microemulsion dispersion. Surface morphology study with transmission electron microscope showed discrete spherical nano sized globules with smooth surface. In-vivo pharmacokinetic study of optimized microemulsion formulation in Wistar rats showed 4.29-fold enhancements in bioavailability. Stability study showed adequate results for various parameters checked up to six months. These results reveal the potential of microemulsion for significant improvement in oral bioavailability of poorly soluble raloxifene hydrochloride.

摘要

本工作旨在利用微乳液的潜力来提高盐酸雷洛昔芬(一种生物利用度为 2%的 BCS 类 II 药物)的口服生物利用度。通过水滴定法用 Capmul MCM C8、Tween 20 和聚乙二醇 400 分别作为油相、表面活性剂和助表面活性剂制备载药微乳液。在油相与表面活性剂混合物之间构建伪三元相图,以获得适当的组成及其浓度范围,从而使微乳液的存在区域较大。D-最优混合设计被用作一种统计工具,用于优化微乳液,考虑油、S 和水作为独立变量,以透光率和液滴尺寸作为依赖变量。优化的配方显示 100±0.1%的透光率和 17.85±2.78nm 的液滴尺寸,与设计专家软件给出的依赖变量的预测值完全相同。与普通药物混悬剂相比,优化的微乳液显示出明显的释放速率增强,遵循 Higuchi 模型的扩散控制释放机制。配方显示出值为-5.88±1.14mV 的 ζ 电位,这赋予载药微乳液分散体良好的稳定性。透射电子显微镜的表面形态研究显示出离散的球形纳米尺寸液滴,表面光滑。在 Wistar 大鼠中的优化微乳液制剂的体内药代动力学研究表明,生物利用度提高了 4.29 倍。稳定性研究表明,在长达六个月的时间内,各种参数的检查结果都足够。这些结果表明微乳液具有显著提高难溶性盐酸雷洛昔芬口服生物利用度的潜力。

相似文献

1
Oral bioavailability enhancement of raloxifene by developing microemulsion using D-optimal mixture design: optimization and in-vivo pharmacokinetic study.采用 D-最优混合设计研制微乳提高雷洛昔芬的口服生物利用度:优化及体内药代动力学研究。
Drug Dev Ind Pharm. 2018 Apr;44(4):687-696. doi: 10.1080/03639045.2017.1408643. Epub 2017 Dec 4.
2
In situ misemgel as a multifunctional dual-absorption platform for nasal delivery of raloxifene hydrochloride: formulation, characterization, and in vivo performance.原位胶凝作为盐酸雷洛昔芬经鼻给药的多功能双重吸收平台:配方、表征和体内性能。
Int J Nanomedicine. 2018 Oct 11;13:6325-6335. doi: 10.2147/IJN.S181587. eCollection 2018.
3
Formulation, development and optimization of raloxifene-loaded chitosan nanoparticles for treatment of osteoporosis.载雷洛昔芬壳聚糖纳米粒的制备、研制与优化及其在骨质疏松治疗中的应用。
Drug Deliv. 2015;22(6):823-36. doi: 10.3109/10717544.2014.900153. Epub 2014 Apr 14.
4
Preparation, characterization and in vitro evaluation of microemulsion of raloxifene hydrochloride.盐酸雷洛昔芬微乳剂的制备、表征及体外评价
Drug Dev Ind Pharm. 2017 Oct;43(10):1619-1625. doi: 10.1080/03639045.2017.1328430. Epub 2017 May 19.
5
Formulation Optimization and Ex Vivo and In Vivo Evaluation of Celecoxib Microemulsion-Based Gel for Transdermal Delivery.塞来昔布微乳凝胶经皮给药的制剂优化及体内外评价
AAPS PharmSciTech. 2017 Aug;18(6):1960-1971. doi: 10.1208/s12249-016-0667-z. Epub 2016 Dec 2.
6
A Self-microemulsifying Drug Delivery System (SMEDDS) for a Novel Medicative Compound Against Depression: a Preparation and Bioavailability Study in Rats.一种用于新型抗抑郁药物化合物的自微乳化药物递送系统(SMEDDS):大鼠体内的制备及生物利用度研究
AAPS PharmSciTech. 2015 Oct;16(5):1051-8. doi: 10.1208/s12249-014-0280-y. Epub 2015 Feb 6.
7
Anticancer efficacy, tissue distribution and blood pharmacokinetics of surface modified nanocarrier containing melphalan.载有美法仑的表面修饰纳米载体的抗癌功效、组织分布和血药动力学。
Int J Pharm. 2012 Apr 15;426(1-2):219-230. doi: 10.1016/j.ijpharm.2012.01.027. Epub 2012 Jan 24.
8
Nanoemulsion liquid preconcentrates for raloxifene hydrochloride: optimization and in vivo appraisal.盐酸雷洛昔芬纳米乳前体液:优化与体内评价。
Int J Nanomedicine. 2012;7:3787-802. doi: 10.2147/IJN.S33186. Epub 2012 Jul 18.
9
Solid self-nanoemulsifying drug delivery system (S-SNEDDS) of darunavir for improved dissolution and oral bioavailability: In vitro and in vivo evaluation.达芦那韦固体自纳米乳化药物递送系统(S-SNEDDS)用于改善溶解性能和口服生物利用度:体外和体内评价
Eur J Pharm Sci. 2015 Jul 10;74:1-10. doi: 10.1016/j.ejps.2015.03.024. Epub 2015 Apr 3.
10
Mixed surfactant based (SNEDDS) self-nanoemulsifying drug delivery system presenting efavirenz for enhancement of oral bioavailability.基于混合表面活性剂的(SNEDDS)自微乳药物传递系统,呈现依非韦伦,以提高口服生物利用度。
Biomed Pharmacother. 2016 May;80:42-51. doi: 10.1016/j.biopha.2016.02.039. Epub 2016 Mar 14.

引用本文的文献

1
An update on selective estrogen receptor modulator: repurposing and formulations.选择性雌激素受体调节剂的最新进展:重新利用与制剂
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jan 16. doi: 10.1007/s00210-024-03753-w.
2
Quality-by-design-based microemulsion of disulfiram for repurposing in melanoma and breast cancer therapy.基于质量源于设计的二甲双胍微乳用于黑色素瘤和乳腺癌治疗的再利用。
Ther Deliv. 2024;15(7):521-544. doi: 10.1080/20415990.2024.2363136. Epub 2024 Jul 1.
3
Simplex Lattice Design and Machine Learning Methods for the Optimization of Novel Microemulsion Systems to Enhance p-Coumaric Acid Oral Bioavailability: In Vitro and In Vivo Studies.
simplex 格子设计和机器学习方法优化新型微乳液系统以提高 p-香豆酸口服生物利用度:体外和体内研究。
AAPS PharmSciTech. 2024 Mar 6;25(3):56. doi: 10.1208/s12249-024-02766-1.
4
Formulation and Evaluation of a Self-Microemulsifying Drug Delivery System of Raloxifene with Improved Solubility and Oral Bioavailability.雷洛昔芬自微乳化药物传递系统的制剂研发与评价:提高溶解度与口服生物利用度
Pharmaceutics. 2023 Aug 2;15(8):2073. doi: 10.3390/pharmaceutics15082073.
5
D-Optimal Design and Development of a Koumine-Loaded Microemulsion for Rheumatoid Arthritis Treatment: In vivo and in vitro Evaluation.考明载药微乳的 D-最优设计与制备及其治疗类风湿关节炎的体内外评价
Int J Nanomedicine. 2023 Jun 5;18:2973-2988. doi: 10.2147/IJN.S406641. eCollection 2023.
6
Oral sorafenib-loaded microemulsion for breast cancer: evidences from the in-vitro evaluations and pharmacokinetic studies.口服索拉非尼负载型微乳用于乳腺癌:来自体外评价和药代动力学研究的证据。
Sci Rep. 2022 Aug 12;12(1):13746. doi: 10.1038/s41598-022-17333-6.
7
A Cosmeceutical Topical Water-in-Oil Nanoemulsion of Natural Bioactives: Design of Experiment, in vitro Characterization, and in vivo Skin Performance Against UVB Irradiation-Induced Skin Damages.一种天然生物活性物质的化妆品局部水包油纳米乳液:实验设计、体外特性表征以及针对 UVB 辐射诱导皮肤损伤的体内皮肤性能。
Int J Nanomedicine. 2022 Jul 6;17:2995-3012. doi: 10.2147/IJN.S363779. eCollection 2022.
8
Recent Applications of Mixture Designs in Beverages, Foods, and Pharmaceutical Health: A Systematic Review and Meta-Analysis.混合设计在饮料、食品和医药健康领域的最新应用:系统评价与荟萃分析
Foods. 2021 Aug 20;10(8):1941. doi: 10.3390/foods10081941.
9
Bioadhesive polymer/lipid hybrid nanoparticles as oral delivery system of raloxifene with enhancive intestinal retention and bioavailability.生物黏附聚合物/脂质杂化纳米粒作为雷洛昔芬口服给药系统,可增强肠道滞留和生物利用度。
Drug Deliv. 2021 Dec;28(1):252-260. doi: 10.1080/10717544.2021.1872742.